The importance of elevated triglycerides levels in everyday clinical practice – what is worth remembering? Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Sep 30, 2015
Keywords:
triglycerides, hypertriglyceridemia, fenofibrate

Main Article Content

Filip M. Szymański
I Katedra i Klinika Kardiologii Warszawskiego Uniwersytetu Medycznego

Abstract

Different types of dyslipidemia include disorders in concentrations of cholesterol and triglycerides. Following the included in the guidelines of scientific societies supremacy of the assessment and the need to reduce the levels of LDL-C (low-density lipoprotein cholesterol), we often forget how much concentrations triglycerides influence the prognosis. The following report presents current views on the importance of the presence of elevated triglycerides levels in assessing the prognosis of patients, along with pharmacological methods of reducing triglycerides concentration, especially with the use of a preferred drug – fenofibrate.

Downloads

Download data is not yet available.

Article Details

How to Cite
Szymański , F. M. (2015). The importance of elevated triglycerides levels in everyday clinical practice – what is worth remembering?. Cardiology in Practice, 9(3), 11-16. Retrieved from https://journalsmededu.pl/index.php/kwp/article/view/1333
Issue
Vol 9 No 3 (2015)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Wożakowska-Kapłon B., Filipiak K.J., Mamcarz A. et al.: Aktualne problemy terapii dyslipidemii w Polsce – II Deklaracja Sopocka. Stanowisko grupy ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Kardiol. Pol. 2014; 72: 847-853.
2. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z., Catapano A.L., De Backer G. et al.; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees: ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 2011; 32: 1769-1818.
3. Berglund L., Brunzell J.D., Goldberg A.C. et al.; Endocrine Society: Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical
practice guideline. J. Clin. Endocrinol. Metab. 2012; 97: 2969-2989.
4. Sidhu D., Naugler C.: Fasting time and lipid levels in a community-based population: a cross-sectional study. Arch. Intern. Med. 2012; 172: 1707-1710.
5. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A.: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299-308.
6. Bansal S., Buring J.E., Rifai N. et al.: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298: 309-316.
7. Mora S., Rifai N., Buring J.E., Ridker P.M.: Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008; 118: 993-1001.
8. Stalenhoef A.F., de Graaf J.: Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small, dense LDL. Curr. Opin. Lipidol. 2008; 19: 355-361.
9. Schwartz G.G., Abt M., Bao W. et al.: Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J. Am. Coll. Cardiol. 2015; 65: 2267-2275.
10. Nordestgaard B.G., Varbo A.: Triglycerides and cardiovascular disease. Lancet 2014; 384: 626-635.
11. Keating G.M., Croom K.F.: Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 2007; 67: 121-153.
12. Ginsberg H.N., Elam M.B., Lovato L.C. et al.; ACCORD Study Group: Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 2010; 362: 1563-1574.
13. Barter P.J., Rye K.A.: Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler. Thromb. Vasc. Biol. 2008; 28: 39-46.
14. The ACCORD Study Group and ACCORD Eye Study Group: Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. N. Engl. J. Med. 2010; 363: 233-244.
15. Keech A.C., Mitchell P., Summanen P.A. et al.: Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687-1697.